Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (22512)	6/19/1998 8:58:00 AM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 32384

Henry, As you know, my notes clearly indicate that D.R. clearly said that LGND's androgen program was larger than any other company's, including any pharma's.

To: Henry Niman who wrote (22512)	6/19/1998 9:49:00 AM
From: WTDEC	Respond to of 32384

Henry, I'll check when I get home late tonight. My recollection is the same as Bernie's, namely that androgen program at LGND is bigger than even large pharmas, way out front on technology, etc. Walter

To: Henry Niman who wrote (22512)	6/20/1998 9:37:00 PM
From: WTDEC	Read Replies (2) \| Respond to of 32384

Henry, as promised I checked my San Diego notes pertaining to LGND's androgen program. Here they are word for word (DR was the speaker): "LGND has both androgen antagonists and agonists. Largest program in the world, even including big pharma - - 35 scientists and growing. You will here a lot about it in the next 12 months, holding this program for LGND now, but big pharmas are extremely interested." (Idouble checked the 35. That is what my notes show, but it is possible 75 is correct as I was writing very fast.) I'm not sure why, but this then appears in my notes: "DR says potential for osteo and HRT ALONE equivalent in size to largest biotech." And after DR talked a little about a new leptin signal modulator program (a long term obesity project): "LGND 1331- Androgen antagonist, due in humans next year. DR very excited, says targets heursuitism, prostate cancer, balding. Androgen agonist" --- (my notes stop here on this topic but he did talk a bit about the agonist.) The next topic was the oral replacement for interferon, which he again could hardly contain his excitement. He stressed it needed more work, but felt they would be in humans in 2001. Hope this was helpful. Regards, Walter